FYN and early-onset autosomal dominant Alzheimer disease: First, AZD0530 has a good inhibitory effect on Fyn within the low nM range (22), and second, clinical trials have shown that AZD0530 is safe and well tolerated in patients with Alzheimer’s disease or tumors (23,24).